Trusted Resource for Clinical Trials, Protocols & Progress
IND on a Budget—What Not to Cut (Small Sponsor Tactics) IND on a Budget—Smart Cuts, Not Blind Cuts: Small-Sponsor Tactics that Preserve Speed and Reviewability Outcome-Oriented Budgeting: Buy Time, De-Risk Holds, and Keep Your First-Patient-In Date Define the decision gates before you cut a dollar Lean programs win by funding decisions, not documents. Before trimming,…
Read More “IND on a Budget—What Not to Cut (Small Sponsor Tactics)” »
Rare-Disease Enrollment Playbook: Windows, Support, Partnerships Rare-Disease Enrollment Playbook: Managing Windows, Building Support, and Structuring Partnerships That Actually Deliver Why rare-disease enrollment is different—and the operating model that makes it predictable What breaks in “business-as-usual” enrollment for rare conditions In rare diseases, enrollment fails for structural reasons: low prevalence spread across wide geographies, heterogeneous diagnostic…
Read More “Rare-Disease Enrollment Playbook: Windows, Support, Partnerships” »
US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice Early Advice Pathways Compared: Getting Actionable FDA Meeting Outcomes vs EMA Scientific Advice (with UK/Global Notes) Why early advice determines your development velocity—and how to aim for decisionable outcomes Begin with a decision map, not a calendar Whether you pursue US or EU first,…
Read More “US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice” »
Right-First-Time IND Cover Letters & Cross-References (US-First) Right-First-Time IND Cover Letters and Cross-Reference Strategy: A US-First, Inspection-Ready Playbook Why the IND cover letter is your speed lever—and how to write one that gets triaged fast Start with decisions, not descriptions The best IND cover letters are not courtesies; they are decision memos disguised as letters….
Read More “Right-First-Time IND Cover Letters & Cross-References (US-First)” »
Investigator Meeting Content Map: Drive Screen Quality Day-1 Investigator Meeting Content Map to Drive Day-1 Screening Quality (and Keep It Inspection-Ready) What an Investigator Meeting must deliver: reproducible screen quality from the very first patient The outcome we’re buying with an IM The point of an Investigator Meeting (IM) is not inspiration—it is repeatable performance….
Read More “Investigator Meeting Content Map: Drive Screen Quality Day-1” »
Type A/B/C Meetings: Questions That Get Actionable FDA Feedback Type A/B/C Meetings: Crafting Questions That Get Actionable FDA Feedback the First Time Outcome-first framing: the fastest path to “clear, actionable” answers Start with the decision you want, then write backwards Every successful Agency interaction starts with a decision list: what you want the review team…
Read More “Type A/B/C Meetings: Questions That Get Actionable FDA Feedback” »
Patient Materials That Convert: Plain-Language, Consent, Burden Patient Materials That Convert: Turning Plain-Language Consent and Burden Transparency into Real Enrollment Why conversion-ready patient materials decide enrollment velocity—and how to make them inspection-proof Define “conversion” the regulator-friendly way Recruitment collateral isn’t successful because it’s beautiful; it’s successful when it predicts informed consent and sustained participation. In…
Read More “Patient Materials That Convert: Plain-Language, Consent, Burden” »
IDE vs IND: Device vs Drug Pathways—How US Sponsors Decide IDE vs IND in the US: A Practical, Inspection-Ready Playbook for Choosing Between Device and Drug Pathways Outcome-oriented framing: how to pick the right pathway without losing months Start with the clinical objective and primary mode of action (PMOA) The fastest route to first-patient-in is…
Read More “IDE vs IND: Device vs Drug Pathways—How US Sponsors Decide” »
Country Mix Optimization: Add Sites with Predictable Gains Country Mix Optimization: How to Add Sites That Deliver Predictable Gains (Not Just More Complexity) Outcome-first site expansion: when adding countries lifts velocity—and when it only adds noise The real question: will a new country raise weekly randomizations with confidence? “Add more sites” is a reflex; “add…
Read More “Country Mix Optimization: Add Sites with Predictable Gains” »
FDA BIMO Expectations: Inspection Readiness from Day 0 Building Day-0 Inspection Readiness: Meeting FDA BIMO Expectations with Evidence, Control, and Operational Rhythm What “Day-0 inspection readiness” really means—and why it accelerates US programs Define the goal in operational terms “Day-0 inspection readiness” means that if an investigator appeared today, the study’s conduct and records would…
Read More “FDA BIMO Expectations: Inspection Readiness from Day 0” »
